OraSure Technologies (NASDAQ:OSUR) Announces Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Key Points

• OraSure reported Q1 EPS of ($0.24), missing the consensus by $0.08, and posted a GAAP operating loss of $23.3 million with a negative net margin of ~59.8%, though revenue was $27.9 million and non‑GAAP gross margin expanded to 43.4% due to insourcing.
• Management expects mid‑2026 FDA clearances and commercial launches for the CT/NG rapid molecular OTC self‑test and the Colli‑Pee, targeting revenue ramps in the second half of 2026 while warning that R&D and G&A are elevated now but should normalize later in 2026.
• The company finished Q1 with $177 million cash and zero debt, has returned $20 million via buybacks, but generated negative operating cash flow of $14 million and is targeting break‑even operating cash flow in 2027; insiders (CEO and CFO) recently purchased shares.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) issued its quarterly earnings results on Wednesday. The medical instruments supplier reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.08), FiscalAI reports. OraSure Technologies had a negative return on equity of 16.45% and a negative net margin of 59.76%.

Here are the key takeaways from OraSure Technologies' conference call:

• Management expects mid-year FDA clearances and commercial launches for its CT/NG rapid molecular OTC self-test and the Colli‑Pee at‑home urine collection device, with revenue ramps anticipated in the second half of 2026.
• Q1 revenue was $27.9 million (above guidance midpoint) and non‑GAAP gross margin expanded to 43.4%, driven by insourcing production into its Pennsylvania facilities and improved operating efficiencies.
• OraSure finished Q1 with $177 million cash and zero debt while returning $20 million to shareholders via buybacks over the last four quarters, but operating cash flow was negative $14 million with management targeting break‑even cash flow in 2027.
• International progress includes initial orders to a nearshoring partner, planned follow‑on orders in H2, and expanded reach for Sickle SCAN via BioMedomics integration and national health program relationships.
• Operating expenses remain elevated—Q1 R&D was $13.7 million (launch preparation) and G&A rose due to severance and one‑time items—contributing to a GAAP operating loss of $23.3 million, though management expects R&D and G&A to normalize later in 2026.

OraSure Technologies Stock Performance

OSUR remained flat at $3.00 during trading on Wednesday. 583,251 shares of the company's stock traded hands, compared to its average volume of 324,072. OraSure Technologies has a 12 month low of $2.08 and a 12 month high of $3.82. The stock's 50-day moving average is $3.05 and its 200 day moving average is $2.76. The stock has a market capitalization of $215.91 million, a price-to-earnings ratio of -3.23 and a beta of 0.89.

Insider Activity at OraSure Technologies

In other OraSure Technologies news, CEO Manner Carrie Eglinton acquired 32,300 shares of the firm's stock in a transaction on Friday, March 20th. The stock was bought at an average cost of $2.93 per share, for a total transaction of $94,639.00. Following the completion of the purchase, the chief executive officer directly owned 2,190,874 shares in the company, valued at $6,419,260.82. This represents a 1.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Kenneth J. Mcgrath bought 32,300 shares of the firm's stock in a transaction dated Friday, March 20th. The stock was purchased at an average price of $2.93 per share, with a total value of $94,639.00. Following the completion of the purchase, the chief financial officer directly owned 589,562 shares of the company's stock, valued at approximately $1,727,416.66. This trade represents a 5.80% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have acquired 108,643 shares of company stock valued at $321,407. 3.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OSUR. Amundi purchased a new position in shares of OraSure Technologies in the first quarter valued at $47,000. AQR Capital Management LLC boosted its stake in shares of OraSure Technologies by 48.3% in the first quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier's stock valued at $3,511,000 after purchasing an additional 339,493 shares during the period. NewEdge Advisors LLC boosted its stake in shares of OraSure Technologies by 32,595.9% in the first quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier's stock valued at $161,000 after purchasing an additional 47,590 shares during the period. Empowered Funds LLC boosted its stake in shares of OraSure Technologies by 7.2% in the first quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier's stock valued at $1,366,000 after purchasing an additional 27,310 shares during the period. Finally, Envestnet Asset Management Inc. boosted its stake in shares of OraSure Technologies by 32.7% in the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier's stock valued at $99,000 after purchasing an additional 8,133 shares during the period. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a "sell (d)" rating on shares of OraSure Technologies in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Reduce" and a consensus price target of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company's flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.